Benzbromarone-Controlled, Double-Blind, Comparative Study of FYU-981 in Hyperuricemia With or Without Gout
Status:
Completed
Trial end date:
2018-08-31
Target enrollment:
Participant gender:
Summary
FYU-981 or Benzbromarone are administrated to hyperuricemia patients with or without gout for
14 weeks to compare the efficacy and safety of these drugs by the method of multicenter,
randomized, double-blind, ascending dose regimen.